Sinovac Biotech

Sinovac Amends Shareholder Rights Plan

Retrieved on:

星期三, 二月 22, 2023

Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.

Key Points:

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.
The amendment extends the expiration date of the plan from February 22, 2023 to February 22, 2024.

China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com

Retrieved on:

星期二, 一月 31, 2023

As a result, China has drawn significant attention to the vaccine industry to play a representative role.

Key Points:

As a result, China has drawn significant attention to the vaccine industry to play a representative role.
In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

CGTN: China's COVID-19 vaccines proven safe, effective by trials and data

Retrieved on:

星期三, 一月 18, 2023

BEIJING, Jan. 18, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.

Key Points:

BEIJING, Jan. 18, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.
China is the only country with COVID-19 vaccines developed via multiple technical routes – they work in different ways.
Chinese companies also made viral vector vaccines and protein subunit vaccines to give people more options.
The Chinese vaccines are precious achievements of the country's fight against COVID-19, which also benefited people in many other countries.

CGTN: China's COVID-19 vaccines proven safe, effective by trials and data

Retrieved on:

星期二, 一月 17, 2023

BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.

Key Points:

BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.
China is the only country with COVID-19 vaccines developed via multiple technical routes – they work in different ways.
Chinese companies also made viral vector vaccines and protein subunit vaccines to give people more options.
The Chinese vaccines are precious achievements of the country's fight against COVID-19, which also benefited people in many other countries.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on:

星期二, 十二月 20, 2022

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points:

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on:

星期二, 十二月 20, 2022

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points:

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on:

星期四, 十二月 15, 2022

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points:

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on:

星期四, 十二月 15, 2022

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points:

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on:

星期五, 十一月 4, 2022

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points:

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on:

星期五, 十月 28, 2022

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points:

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.